David B. Kaminsky, M.D., FIAC, March 20, 2018
Original release date:
April 25, 2018
Access to this course expires on:
March 20, 2021
Stanley R. Hamilton, M.D., Head, Division of Pathology & Laboratory Medicine Medicine, Frederick F. Becker Distinguished University Chair in Cancer Research, University of Texas, MD Anderson Cancer Center
Continuing Medical Education and Maintenance of Certification:
- Describe the roles of the pathologist in the pre-analytic, analytic, and post-analytic phases of integral biomarker assays for individualized cancer therapy.
- Describe the goals of the Molecular Analysis for Therapy Choice (NCI-MATCH, EAY-131) clinical trial and discuss the implications of the outcomes.
- Define "liquid biopsy" and describe the advantages and disadvantages of various specimen sources and analytes.
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 1
AMA PRA Category 1 CreditsTM
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported no relevant financial relationships: Stanley R. Hamilton, M.D.
USCAP staff associated with the development of content for this activity reported no relevant financial relationships.
Use Promo Code MaudeAbbott2018 at checkout to access this lecture for FREE!